There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant
activity in myelofibrosis.